

Date: 08 February 2025

To

The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code: 544293	The Secretary The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1. G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 Scrip Symbol : SURAKSHA
---	--

Dear Sir / Ma'am,

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Sub: Outcome of Board Meeting held on 08 February 2025

With reference to our earlier intimation dated 03 February 2025, the Board of Directors of the Company, at its meeting held today, i.e. 08 February 2025 have, inter alia, considered and approved the following matters:

1. The unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended 31 December 2024 and the same is enclosed along with the Limited Review Report issued by the Statutory Auditors of the Company, pursuant to Regulation 33 of SEBI Listing Regulations marked as "**Annexure-A**";
2. Based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, appointment of Mr. Ravindra K S as the Chief Financial Officer with effect from 01 March 2025, who will also act as a Group Chief Financial Officer.

The details as required under Schedule III - Para A (7) of Part A of Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 is marked as "**Annexure-B**".

3. Amendment in the following policies of the Company in compliance with the recent amendments specified in SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulation, 2024 and SEBI (Prohibition of Insider Trading) (Third Amendment) Regulations, 2024:
 - a. Code of Conduct for Directors and Senior Management
 - b. Material Subsidiaries Policy
 - c. Policy on Disclosure of Material Events
 - d. Related Party Transaction Policy
 - e. Code of Conduct for Insider Trading

Suraksha Diagnostic Limited

(Formerly known as Suraksha Diagnostic Private Limited)

CIN: L85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town,
Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone:(033) 6605 9750

The above-mentioned policies shall be available on the website of the Company at www.surakshanet.com. This shall be treated as compliance as per Regulations 46 of the Listing Regulations.

Please note that the meeting commenced at 4.00 pm (IST) and concluded at 4.32 pm (IST).

You are requested to take the same on record.

Thanking you.

For Suraksha Diagnostic Limited

Mamta Jain
Company Secretary and Compliance Officer

Encl.: as above

Independent Auditor's Review Report on unaudited standalone financial results of Suraksha Diagnostic Limited (formerly known as Suraksha Diagnostic Private Limited) for the quarter and year to date ended December 31, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of Suraksha Diagnostic Limited (formerly known as Suraksha Diagnostic Private Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Suraksha Diagnostic Limited (formerly known as Suraksha Diagnostic Private Limited) (hereinafter referred to as 'the Company') for the quarter ended December 31, 2024 and the year-to-date results for the period from April 01, 2024 to December 31, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MSKA & Associates


Chartered Accountants

Independent Auditor's Review Report on unaudited standalone financial results of Suraksha Diagnostic Limited (formerly known as Suraksha Diagnostic Private Limited) for the quarter and year to date ended December 31, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (cont'd)

5. The Statement includes results for the quarter and the year-to-date ended December 31, 2023 that have been approved by the Board of Directors and have not been subject to review or audit by us or by another auditor.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Dipak Jaiswal
Membership No.: 063682
UDIN: 25063682BMOTNC8001



Place: Kolkata
Date: February 08, 2025

Suraksha Clinic & Diagnostics

Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited)
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Statement of unaudited standalone financial results for the quarter and nine months ended December 31, 2024

(Rs in lakhs)

Particulars	Quarter ended			Nine months ended		Year ended
	December 31, 2024 (Unaudited)	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited) (refer note 3)	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited) (refer note 3)	March 31, 2024 (Audited) (refer note 6)
Income						
Revenue from operations	5,857.00	6,594.74	5,145.44	18,495.03	16,315.43	21,852.47
Other income	97.45	125.55	83.49	344.09	259.31	364.76
Total Income	5,954.45	6,720.29	5,228.93	18,839.12	16,574.74	22,217.23
Expenses						
Cost of materials consumed	598.82	782.71	621.23	2,035.65	2,057.34	2,712.66
Employee benefits expenses	1,101.42	1,071.10	1,020.21	3,191.06	3,078.49	3,963.93
Finance costs	203.29	207.39	198.01	632.20	666.53	878.83
Depreciation and amortisation expense	861.55	857.66	791.91	2,606.90	2,423.89	3,256.70
Other expenses	2,347.47	2,383.61	1,946.89	6,991.40	6,052.71	8,056.71
Total expenses	5,112.55	5,302.47	4,578.25	15,457.21	14,278.96	18,868.83
Profit before tax and exceptional items	841.90	1,417.82	650.68	3,381.91	2,295.78	3,348.40
Exceptional items	-	-	-	-	-	77.88
Profit before tax	841.90	1,417.82	650.68	3,381.91	2,295.78	3,270.52
Income tax expense						
Current tax	215.41	357.73	171.72	882.30	660.70	946.46
Deferred tax	(9.20)	(14.50)	(14.04)	(43.72)	(119.20)	(114.33)
Total tax expense	206.21	343.23	157.68	838.58	541.50	832.13
Profit for the period/year	635.69	1,074.59	493.00	2,543.33	1,754.28	2,438.39
Other comprehensive income						
Items that will not be reclassified subsequently to profit or loss						
Remeasurement gain/(loss) of net defined benefit plan	16.35	4.60	-	(18.78)	-	(19.19)
Income tax effect on above	(4.11)	(1.16)	-	4.73	-	4.83
Other comprehensive income/(losses) for the period/year, net of tax	12.24	3.44	-	(14.05)	-	(14.36)
Total comprehensive income for the period/year	647.93	1,078.03	493.00	2,529.28	1,754.28	2,424.03
Paid-up equity share capital (face value - Rs. 2 per share)	1,041.62	862.50	690.00	1,041.62	690.00	690.00
Other equity	-	-	-	-	-	17,233.63
Earnings per equity share (Face Value of Rs 2 each)						
- Basic (Rs) (not annualised except for year end figures)	1.22	2.02	0.92	4.88	3.29	4.57
- Diluted (Rs) (not annualised except for year end figures)	1.22	2.02	0.92	4.88	3.29	4.57

Notes to the unaudited standalone financial results

1. The unaudited standalone financial results for the quarter and nine months period ended December 31, 2024 ("the financial results") of Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited) ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").

2. These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on February 08, 2025. The statutory auditors have carried out limited review on these financial results and have issued an unmodified conclusion.

3. The figures for the corresponding quarter and nine months period ended December 31, 2023 are presented based on the information complied by the management in accordance with Ind AS and have not been subject to review or audit by the statutory auditors or by any other auditor. However, the management has prepared the results for the said periods by applying consistent accounting policies.

4. During the quarter ended December 31, 2024, the Company has completed an Initial Public Offering entirely as offer for sale of 1,91,89,330 equity shares by existing share holders with face value of Rs.2 and got listed on both National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on December 06, 2024.

5. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 - Operating Segments.

6. The figures for the year ended March 31, 2024 have been extracted from the general purpose standalone financial statements of the Company which were audited by the statutory auditors of the Company.

7. During the quarter ended December 31, 2024, 0.0001% Compulsorily Convertible Preference Shares aggregating to 1,62,859 preference shares of par value Rs 100 each were converted into 89,55,761 equity shares of par value of Rs 2 each.

8. During the quarter ended December 31, 2024, the Nomination and Remuneration Committee ("the NRC") has approved grant of 2,08,164 stock options to employees under the Suraksha Employee Stock Option Scheme 2024 ("ESOP" / "Scheme"). The Company has accounted for these stock options in accordance with Ind AS 102 - Share Based Payments.

9. These financial results are also available on the Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseindia.com).

For and on behalf of Board of Directors of
Suraksha Diagnostic Limited
(formerly known as Suraksha Diagnostic Private Limited)



Dr. Somnath Chatterjee
Chairman and Joint Managing Director
DIN: 00137075

Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : U85110WB2005PLC102265

Place: Kolkata
Date: February 08, 2025

Independent Auditor's Review Report on unaudited consolidated financial results of Suraksha Diagnostic Limited (formerly known as Suraksha Diagnostic Private Limited) for the quarter and year to date ended December 31, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Suraksha Diagnostic Limited (formerly known as Suraksha Diagnostic Private Limited)

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Suraksha Diagnostic Limited (formerly known as Suraksha Diagnostic Private Limited) (hereinafter referred to as 'the Holding Company') and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2024 and the year-to-date results for the period from April 01, 2024 to December 31, 2024 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Independent Auditor's Review Report on unaudited consolidated financial results of Suraksha Diagnostic Limited (formerly known as Suraksha Diagnostic Private Limited) for the quarter and year to date ended December 31, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (cont'd)

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Suraksha Specialty LLP	Subsidiary
2	Asian Institute of Immunology & Rheumatology LLP (AIIR)	Subsidiary
3	Suraksha Radiology Private Limited	Subsidiary
4	Suraksha Salvia LLP	Step Down Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of four subsidiaries included in the Statement, whose interim financial results reflects total revenues of Rs.142.70 lakhs and Rs. 307.89 lakhs, total net loss after tax of Rs. 37.48 lakhs and Rs.163.24 lakhs and total comprehensive loss of Rs. 37.48 lakhs and Rs.163.24 lakhs, for the quarter ended December 31, 2024 and for the period from April 01, 2024 to December 31, 2024, respectively, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.



Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and reports of the other auditors.

Independent Auditor's Review Report on unaudited consolidated financial results of Suraksha Diagnostic Limited (formerly known as Suraksha Diagnostic Private Limited) for the quarter and year to date ended December 31, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (cont'd)

7. The Statement includes results for the quarter and the year-to-date results ended December 31, 2023 that have been approved by the Board of Directors and have not been subject to review or audit by us or by another auditors.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Dipak Jaiswal
Membership No.: 063682
UDIN: 25063682BMOTND6878



Place: Kolkata
Date: February 08, 2025

Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited)
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Statement of unaudited consolidated financial result for the quarter and nine months ended December 31, 2024

Particulars	Quarter ended			Nine months ended		Year ended
	December 31, 2024 (Unaudited)	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited) (refer note 3)	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited) (refer note 3)	March 31, 2024 (Audited) (refer note 6)
Income						
Revenue from operations	5,951.30	6,675.35	5,182.06	18,699.80	16,352.05	21,870.85
Other income	59.91	131.32	84.87	302.92	257.16	355.09
Total Income	6,011.21	6,806.67	5,266.93	19,002.72	16,609.21	22,225.94
Expenses						
Cost of materials consumed	610.32	793.12	631.35	2,067.11	2,067.46	2,725.12
Employee benefits expenses	1,128.66	1,102.12	1,031.74	3,268.69	3,107.15	4,006.81
Finance costs	198.15	212.53	202.52	632.20	671.04	878.83
Depreciation and amortisation expense	882.72	874.89	791.91	2,656.89	2,423.89	3,259.80
Other expenses	2,386.69	2,460.72	1,987.55	7,158.55	6,117.66	8,132.25
Total expenses	5,206.54	5,443.38	4,645.07	15,783.44	14,387.20	19,002.81
Profit before tax and exceptional items	804.67	1,363.29	621.86	3,219.28	2,222.01	3,223.13
Exceptional items	-	-	-	-	-	77.88
Profit before tax	804.67	1,363.29	621.86	3,219.28	2,222.01	3,145.25
Income tax expense						
Current tax	215.41	357.73	182.14	882.30	660.70	946.96
Deferred tax	(9.20)	(10.00)	(14.04)	(43.72)	(119.20)	(114.33)
Total tax expense	206.21	347.73	168.10	838.58	541.50	832.63
Profit for the period/year	598.46	1,015.56	453.76	2,380.70	1,680.51	2,312.62
Other comprehensive income						
Items that will not be reclassified subsequently to profit or loss						
Remeasurement gain/(loss) of net defined benefit plan	16.35	4.60	-	(18.78)	-	(19.19)
Income tax effect on above	(4.11)	(1.16)	-	4.73	-	4.83
Other comprehensive income/(losses) for the period/ year, net of tax	12.24	3.44	-	(14.05)	-	(14.36)
Total comprehensive income for the period/year	610.70	1,019.00	453.76	2,366.65	1,680.51	2,298.26
Profit for the period/year attributable to						
Owners of the parent	615.36	1,034.29	465.38	2,443.54	1,710.49	2,362.54
Non- controlling interests	(16.90)	(18.73)	(11.62)	(62.84)	(29.98)	(49.92)
	598.46	1,015.56	453.76	2,380.70	1,680.51	2,312.62
Other comprehensive income for the period/year attributable to						
Owners of the parent	12.24	3.44	-	(14.05)	-	(14.36)
Non- controlling interests	-	-	-	-	-	-
	12.24	3.44	-	(14.05)	-	(14.36)
Total comprehensive income for the period/year attributable to						
Owners of the parent	627.60	1,037.73	465.38	2,429.49	1,710.49	2,348.18
Non- controlling interests	(16.90)	(18.73)	(11.62)	(62.84)	(29.98)	(49.92)
	610.70	1,019.00	453.76	2,366.65	1,680.51	2,298.26
Paid-up equity share capital (face value - Rs. 2 per share)	1,041.62	862.50	690.00	1,041.62	690.00	690.00
Other equity (including Non-controlling interest)	-	-	-	-	-	17,087.97
Earnings per equity share (Face Value of 2 each (Rs))						
- Basic (Rs) (not annualised except for year end figures)	1.18	1.94	0.87	4.69	3.21	4.43
- Diluted (Rs) (not annualised except for year end figures)	1.18	1.94	0.87	4.69	3.21	4.43

Notes to the unaudited consolidated financial results

1. The unaudited consolidated financial results for the quarter and nine months period ended December 31, 2024 ("the financial results") of Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited) ("the Holding Company") and its subsidiary (Holding Company and subsidiaries together referred to as "the group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").

2. These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on February 08, 2025. The statutory auditors have carried out limited review on these financial results and have issued an unmodified conclusion.

3. The figures for the corresponding quarter and nine months period ended December 31, 2023 are presented based on the information compiled by the management in accordance with Ind AS and have not been subject to review or audit by the statutory auditors or by any other auditor. However, the management has prepared the results for the said periods by applying consistent accounting policies.



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com


Phone: (033) 66059750 | CIN : U85110WB2005PLC102265

Suraksha Clinic & Diagnostics

4. During the quarter ended December 31, 2024, the Holding Company has completed an Initial Public Offering entirely as offer for sale of 1,91,89,330 equity shares by existing share holders with face value of Rs.2 and got listed on both National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on December 08, 2024.
5. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 – 'Operating Segments'.
6. The figures for the year ended March 31, 2024 have been extracted from the general purpose consolidated financial statements of the Company which were audited by the statutory auditors of the Company.
7. During the quarter ended December 31, 2024, 0.0001% Compulsorily Convertible Preference Shares of the Holding company aggregating to 1,62,859 preference shares of par value Rs 100 each were converted into 89,55,781 equity shares of par value of Rs 2 each.
8. During the quarter ended December 31, 2024, the Nomination and Remuneration Committee ("the NRC") has approved grant of 2,08,164 stock options to employees under the Suraksha Employee Stock Option Scheme 2024 ("ESOP" / "Scheme"). The Holding company has accounted for these stock options in accordance with Ind AS 102 – Share-Based Payments.
9. These financial results are also available on the Holding company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseindia.com).

For and on behalf of Board of Directors of
Suraksha Diagnostic Limited
(formerly known as Suraksha Diagnostic Private Limited)




Dr. Somnath Chatterjee
Chairman and Joint Managing Director
DIN: 00137075

Place: Kolkata
Date: February 08, 2025



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : U85110WB2005PLC102265

Annexure - B

The details as required under Schedule III - Para A (7) of Part A of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	1) Resignation of Mr. Amit Saraf from the position of Chief Financial Officer and Key Managerial Personnel effective on or before 15 February 2025, intimation of which has been given to the stock exchanges on 16 January 2025. 2) Appointment of Mr. Ravindra K S as the Chief Financial Officer with effect from 01 March 2025, who will also act as a Group Chief Financial Officer.
2	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment / re-appointment	The Board of Directors in their meeting held today and based on the recommendation of the Nomination and Remuneration Committee and Audit Committee had considered and approved the appointment of Mr. Ravindra K S as the Chief Financial Officer with effect from 01 March 2025, who will also act as a Group Chief Financial Officer.
3	Brief profile (in case of appointment)	Mr. Ravindra K. S. is a finance professional with more than two decades of experience. He has obtained a bachelor's degree in Commerce from Kuvempu University and has been a member of Institute of Chartered Accountants of India since 2004. He possesses extensive expertise across a wide range of finance functions. Before joining our Company, Ravindra K S was a Group CFO at Medica Hospitals Group. He has also worked as a Group Finance Controller at Narayana Hrudayalaya Limited, Group Manager-Finance at Aditya Birla Nuvo Limited, Manager-Accounts & Finance at Pierian Services Private Limited and as a CAO at Leonardo Engineering Private Limited. His diverse background equips him with a robust understanding of financial management and strategic planning.
4	Disclosure of relationships between Directors (in case of appointment of a Director)	Not Applicable

Suraksha Diagnostic Limited

(Formerly known as Suraksha Diagnostic Private Limited)

CIN: L85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone:(033) 6605 9750